US Supreme Court unanimously backs Hikma in Amarin skinny-labelling patent case

The US Supreme Court issued a unanimous ruling on 4–5 June 2026 in favour of Hikma Pharmaceuticals in a patent dispute with Amarin Pharma over so-called skinny labelling — a regulatory mechanism that allows generic drug manufacturers to gain approval for a drug while omitting patented indications from the label.

Reported by STAT News's Pharmalot, the ruling was seen as a significant win for the generic pharmaceutical industry, clarifying the extent to which manufacturers can use skinny labels without incurring patent infringement liability. The case had attracted attention from drugmakers, patient advocacy groups, and policy observers given its implications for drug pricing and competition.

Whilst this story sits at the margins of genetics and genomics, it has relevance for genetic medicines — including gene therapies and pharmacogenomically informed treatments — that may in future be subject to similar labelling and patent litigation dynamics. It also bears on the broader policy environment for genomic medicine access and affordability discussed elsewhere in Genetic Current.